T세포 면역치료 시장(제3판) : 2018-2030년
T-Cell Immunotherapy Market (3rd Edition), 2018-2030
상품코드 : 342155
리서치사 : ROOTS ANALYSIS
발행일 : 2018년 05월
페이지 정보 : 영문 850 Pages
US $ 3,499 ₩ 3,926,500
PDF by E-mail (Single User License)
US $ 7,999 ₩ 8,976,400
PDF by E-mail (Site License)
US $ 14,999 ₩ 16,831,800
PDF by E-mail (Enterprise License)


한글목차

T세포 면역치료(T-Cell Immunotherapy) 시장을 조사 분석했으며, 현재의 시장 구도와 향후 가능성에 초점을 맞추어 주요 기업, 파이프라인 제품 개발 단계, 제휴 동향, 혁신 기술, 치료 영역, 경쟁 구도 등의 정보를 정리하여 전해드립니다.

제1장 서문

제2장 주요 요약

제3장 서론

제4장 소셜 미디어상의 새로운 동향

제5장 시장 구도

제6장 주요 인사이트

제7장 키메라 항원 수용체 발현 T(CAR-T) 세포 요법

제8장 T세포 수용체(TCR) 기반 요법

제9장 종양 침윤 림프구(TIL) 기반 요법

제10장 T세포 요법의 주요 치료 영역

제11장 새로운 기술

제12장 파트너십과 제휴

제13장 융자 및 투자 분석

제14장 기타 T세포 면역치료

제15장 사례 연구 : 세포 요법 제조

제16장 사례 연구 : 원가 분석

제17장 시장 규모와 기회 분석

제18장 판촉 분석

제19장 기업 개요

제20장 결론

제21장 중요 인사이트

제22장 부록 1 : 도표 데이터

제23장 부록 2 : 기업 및 조직 리스트

LSH 18.05.18

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문 목차

영문목차

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2017 in the US alone. The World Health Organization states that the number of new cancer cases globally is expected to rise by 70% in the coming 20 years. Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Specifically, chemotherapy and radiation therapy are also associated with several side effects. Their non-specific nature has severe detrimental effects on the patients' quality of life.

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. It encompasses several treatment approaches, such as monoclonal antibodies, immune checkpoint inhibitors, therapeutic vaccines, cytokine therapies and cell-based therapies. In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable therapeutic intervention. There are certain key characteristics that render T-cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

Close to 120 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups; in fact, during the last five years, over USD 8 billion has been invested by VC firms / other strategic investors. It is also worth highlighting that there have been more than 200 instances of collaborations between industry / academic stakeholders. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Encouraged by the recent approval of two CAR-T therapies, namely Kymriah® (Novartis) and Yescarta® (Gilead Sciences), and a robust development pipeline, the T-cell immunotherapy market offers considerable promise to a number of industry stakeholders.

Synopsis:

The “T-Cell Immunotherapy Market, 2018-2030 (3rd edition)” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms. Amongst other elements, the report features the following:

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The report includes potential sales of T-cell immunotherapies that are currently marketed or are in late stages of development. Additionally, the chapter presents a detailed market segmentation on the basis of type of therapy (CAR-T, TCR and TIL), geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer, cervical carcinoma, chronic lymphocytic leukemia, esophageal cancer, head and neck cancer, multiple myeloma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer and synovial sarcoma). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies.

Chapter 4 provides insights on the popularity of T-cell immunotherapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2017, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords and drug candidates, as observed on social media.

Chapter 5 provides information on around 500 T-cell immunotherapies that are currently in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of therapy (CAR-T, TCR and TIL), type of developer(s), phase of development, target therapeutic areas and indications, key target antigens, source of T-cells (autologous and allogenic) and route of administration. Further, the chapter identifies the most active players (in terms of number of pipeline candidates) and features a logo landscape representation, highlighting product developers in North America, Europe and the Asia Pacific region.

Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T and TCR therapies in hematological cancer and solid tumor space. Further, the chapter includes an analysis on global CAR-T trials registered between 2009 to 2018, featuring the year wise trend and distribution of CAR-T trials across different geographies. In addition, it includes comprehensive analysis of more than 400 clinical trials that have been completed or are currently being conducted to evaluate T-cell immunotherapies with respect to the type of T-cell immunotherapy (CAR-T, TCR and TIL), phase of development, patient segment, and type of therapy (monotherapy and combination therapy).

Chapter 7 focuses on CAR-T cell based therapies and highlights the prevailing trends pertaining to ongoing research in this field. It features a discussion on the molecular targets that are currently under investigation and the current challenges (such as toxicity issues) that are associated with this segment. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapy, type of binding domain, type of vector and type of co-stimulatory domain. This section also includes detailed profiles of the approved / late stage CAR-T cell therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.

Chapter 8 focuses on TCR cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It features a discussion on the molecular targets that are currently under investigation and the current challenges (such as toxicity issues) that are associated with this segment. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. This section also includes detailed profiles of the late stage TCR therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.

Chapter 9 elaborates on the TIL based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. This section also includes detailed profiles of the late stage TIL therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.

Chapter 10 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the T-cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 11 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. It features brief profiles of some of the key technologies as well. Each profile contains details on the various pipeline molecules that have been / are being developed using the technology, its advantages and the associated partnerships.

Chapter 12 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others, the companies involved, the type of therapy and prominent product candidates involved.

Chapter 13 provides details on the various investments and grants that have been awarded to players focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2017, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 14 features details of other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on the current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.

Chapter 15 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 16 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 17 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of type of therapy (CAR-T, TCR and TIL), geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer, cervical carcinoma, chronic lymphocytic leukemia, esophageal cancer, head and neck cancer, multiple myeloma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer and synovial sarcoma).

Chapter 18 highlights the key promotional strategies that are being implemented by the developers of the marketed products, Kymriah and Yescarta. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 19 includes brief company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 20 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 21 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Enkhtsetseg Purev (Assistant Professor Of Medicine, University Of Colorado), Miguel Forte (Chief Operating Officer, TxCell), Peter Ho (Director, Process Development, Iovance Biotherapeutics), Tim Oldham (Chief Executive Officer, Cell Therapies), Victor Lietao Li (Co-Founder & Chief Executive Officer, Lion TCR), Vincent Brichard (Vice President, Immuno-Oncology, Celyad) and Xian-Bao Zhan (Professor Of Medicine and Director, Department Of Oncology, Changhai Hospital).

Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 23 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. EMERGING TRENDS ON SOCIAL MEDIA

5. MARKET LANDSCAPE

6. KEY INSIGHTS

7. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY

8. T-CELL RECEPTOR (TCR) BASED THERAPIES

9. TUMOR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES

10. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES

11. EMERGING TECHNOLOGIES

12. PARTNERSHIPS AND COLLABORATIONS

13. FUNDING AND INVESTMENT ANALYSIS

14. OTHER T-CELL IMMUNOTHERAPIES

15. CASE STUDY: CELL THERAPY MANUFACTURING

16. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS

17. MARKET SIZING AND OPPORTUNITY ANALYSIS

18. PROMOTIONAL ANALYSIS

19. COMPANY PROFILES

20. CONCLUSION

21. EXECUTIVE INSIGHTS

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES

List of Figures

List of Tables

Listed Companies

The following companies and organizations have been mentioned in the report:

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기